Workshop for implementing support tools to promote safety in the prescribing of oral contraceptives
Workshop for implementing support tools to promote safety in the prescribing of oral contraceptives
批准号:
10742446
负责人:
Devin Bustin
金额:
$5.4万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-03-01 至 2023-08-31
关键词:
AddressAdoptionComputer softwareContraceptive AgentsContraceptive methodsDataEducational workshopEligibility DeterminationFeedbackFutureGrantHealth Services AccessibilityHealthcare SystemsInnovation CorpsKnowledgeMedical TechnologyMedicineModificationOral ContraceptivesPaperPharmacistsPharmacy facilityPhasePopulationPregnancy RateProcessSafetyServicesSmall Business Innovation Research GrantSystemTechnologyTestingTimeUnited StatesWomancombatcommercializationdesignhealth inequalitiesimprovedinsightinterestmemberpatient safetyprogramsrecruitsupport toolsunintended pregnancyusability
中文摘要
点击翻译按钮获取中文摘要
英文摘要
SUMMARY
The overall objective of our predicate SBIR Phase I grant, which commenced in September 2022, is to
investigate the feasibility of pharmacists utilizing our proprietary OvaryIt software to prescribe contraceptives.
Many states allow pharmacists to prescribe contraception, but the current paper-based process is inefficient
and difficult to incorporate into daily practice for busy pharmacists. Therefore, even though many pharmacists
are eligible to prescribe contraceptives, very few are actively offering these services. There continues to be an
ongoing need for access to contraceptive services in the United States (US), with approximately 19 million
women living in what is deemed a contraceptive desert. Because 90% of the population lives within 5 miles of
a pharmacy, pharmacist-prescribed contraceptive services have the potential to dramatically increase access
to care, decrease inequities in the health care system, and combat the high unintended pregnancy rate in the
US.
During Phase I, the OvaryIt Team has begun networking with numerous pharmacists with diverse backgrounds
from across the US to gather insights and data. In addition to the primary feasibility objective, the team has
recruited subject matter experts to assist in the creation of a comprehensive implementation package that
addresses the barriers to the adoption of pharmacist-prescribed contraceptive services, determine the
technological and operational requirements needed to successfully incorporate the solution into existing
pharmacy workflows, and conduct usability testing to guide incremental improvements to the OvaryIt software.
Early findings support our hypothesis that pharmacists are interested in providing contraceptive services, and
they perceive that utilizing the OvaryIt software increases efficiency, patient safety, and the feasibility of
incorporating contraceptive services into daily practice. Additionally, we received valuable feedback regarding
potential modifications to the user interface that will guide improvements in the future system.
OvaryIt, LLC has assembled a strong team with expertise in project management, contraceptive medicine, and
medical technology design and implementation. All three members are committed to the time requirements of
the program. The OvaryIt Team is willing to modify, adapt, and refine the overall commercialization strategy
based on knowledge gained during the I-Corps Program.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金